<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hansa Biopharma Ab — News on 6ix</title>
<link>https://6ix.com/company/hansa-biopharma-ab</link>
<description>Latest news and press releases for Hansa Biopharma Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 07:21:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hansa-biopharma-ab" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836250678dffbe2df1430ba.webp</url>
<title>Hansa Biopharma Ab</title>
<link>https://6ix.com/company/hansa-biopharma-ab</link>
</image>
<item>
<title>Hansa Biopharma publishes 2025 Annual and Sustainability Reports</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-publishes-2025-annual-and-sustainability-reports</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-publishes-2025-annual-and-sustainability-reports</guid>
<pubDate>Thu, 26 Mar 2026 07:21:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025.</description>
</item>
<item>
<title>PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-7</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-7</guid>
<pubDate>Wed, 04 Mar 2026 23:27:00 GMT</pubDate>
<description>Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026.</description>
</item>
<item>
<title>Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda</guid>
<pubDate>Wed, 18 Feb 2026 19:30:00 GMT</pubDate>
<description>Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA).</description>
</item>
<item>
<title>Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 11 Feb 2026 06:34:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its Q4 2025 and full-year financial results.</description>
</item>
<item>
<title>KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/kdventures-portfolio-company-svf-vaccines-appoints-raheleh-nassaji-as-chief-executive-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/kdventures-portfolio-company-svf-vaccines-appoints-raheleh-nassaji-as-chief-executive-officer-1</guid>
<pubDate>Tue, 10 Feb 2026 12:41:00 GMT</pubDate>
<description>STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine can</description>
</item>
<item>
<title>Hansa Biopharma has won the 2025 SwedenBIO Award</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-has-won-the-2025-swedenbio-award</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-has-won-the-2025-swedenbio-award</guid>
<pubDate>Thu, 22 Jan 2026 12:40:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as the winner among the many nominated companies.</description>
</item>
<item>
<title>Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation</guid>
<pubDate>Fri, 19 Dec 2025 19:46:00 GMT</pubDate>
<description>Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imlifidase. The Company is requesting priority review of the BLA for the use of imlifidase in the desensitization of highly sensitized adult patients undergoing deceased donor kidney transplantation.</description>
</item>
<item>
<title>Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results</guid>
<pubDate>Thu, 30 Oct 2025 06:18:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025.</description>
</item>
<item>
<title>Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-hosts-call-with-distinguished-transplant-surgeons-insights-on-clinical-practice-and-imlifidase-phase-3-results</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-hosts-call-with-distinguished-transplant-surgeons-insights-on-clinical-practice-and-imlifidase-phase-3-results</guid>
<pubDate>Wed, 29 Oct 2025 18:00:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized patients awaiting a kidney transplant and share perspectives on the clinical relevance of the topline results from the US Phase 3 ConfIdeS st</description>
</item>
<item>
<title>Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/data-from-gnt-018-ides-trial-supports-feasibility-of-imlifidase-as-pretreatment-in-gene-therapy-treatment-for-patients-with-crigler-najjar-syndrome-who-are-immune-to-aav</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/data-from-gnt-018-ides-trial-supports-feasibility-of-imlifidase-as-pretreatment-in-gene-therapy-treatment-for-patients-with-crigler-najjar-syndrome-who-are-immune-to-aav</guid>
<pubDate>Fri, 10 Oct 2025 08:00:00 GMT</pubDate>
<description>PARIS, October 10, 2025--A significant advance in treatment of patients with immunity to AAVs previously ineligible for clinical trials and existing gene therapy treatments.</description>
</item>
<item>
<title>Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation</guid>
<pubDate>Wed, 24 Sep 2025 18:13:00 GMT</pubDate>
<description>Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) adult kidney transplant patients with positive crossmatch against a deceased donor, versus the control arm. The trial was well conducted, with patient retention in excess of 90%, and met the primary endpoint of kidney function at 12 months as measured by mean esti</description>
</item>
<item>
<title>Hansa Biopharma announces key executive appointments to support continued growth</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth</guid>
<pubDate>Tue, 29 Jul 2025 16:34:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck Lagercrantz will join the company September 1, as Vice President Corporate Affairs. These three experienced executives will support Hansa's growth and further enhance the company's expertise acros</description>
</item>
<item>
<title>Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results</guid>
<pubDate>Thu, 17 Jul 2025 05:50:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.</description>
</item>
<item>
<title>Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer</guid>
<pubDate>Tue, 08 Jul 2025 06:17:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.</description>
</item>
<item>
<title>Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-presents-positive-outcomes-of-five-year-follow-up-study-of-imlifidase-in-kidney-transplantation-at-esot-congress-2025-in-london</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-presents-positive-outcomes-of-five-year-follow-up-study-of-imlifidase-in-kidney-transplantation-at-esot-congress-2025-in-london</guid>
<pubDate>Mon, 30 Jun 2025 06:17:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.</description>
</item>
<item>
<title>Hansa Biopharma to attend BIO International Convention</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-to-attend-bio-international-convention</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-to-attend-bio-international-convention</guid>
<pubDate>Wed, 11 Jun 2025 07:01:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19.</description>
</item>
<item>
<title>Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-to-host-science-deep-dive-virtual-investor-event-on-guillain-barre-syndrome-on-june-16-2025</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-to-host-science-deep-dive-virtual-investor-event-on-guillain-barre-syndrome-on-june-16-2025</guid>
<pubDate>Mon, 09 Jun 2025 06:11:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025 at 14:00 CEST / 8:00 AM EDT. Pre-registration is required and can be found at this link.</description>
</item>
<item>
<title>Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-data-at-the-2025-pns-annual-meeting-demonstrates-potential-of-imlifidase-in-the-treatment-of-gbs</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-data-at-the-2025-pns-annual-meeting-demonstrates-potential-of-imlifidase-in-the-treatment-of-gbs</guid>
<pubDate>Wed, 14 May 2025 06:28:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotland.</description>
</item>
<item>
<title>Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-appoints-maria-tornsen-as-chief-operating-officer-and-president-us</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-appoints-maria-tornsen-as-chief-operating-officer-and-president-us</guid>
<pubDate>Tue, 13 May 2025 06:26:00 GMT</pubDate>
<description>Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.</description>
</item>
<item>
<title>Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients</title>
<link>https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-completes-enrolment-in-european-phase-3-20-hmedides-19-post-authorization-efficacy-and-safety-study-in-highly-sensitized-kidney-transplant-patients</link>
<guid isPermaLink="true">https://6ix.com/company/hansa-biopharma-ab/news/hansa-biopharma-completes-enrolment-in-european-phase-3-20-hmedides-19-post-authorization-efficacy-and-safety-study-in-highly-sensitized-kidney-transplant-patients</guid>
<pubDate>Tue, 11 Mar 2025 14:08:00 GMT</pubDate>
<description>Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 confirmatory study in Europe investigating the one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase. Imlifidase is the Company's first generation, first-in-class, one-time treat</description>
</item>
</channel>
</rss>